Drug Portfolios and Clinical Pipelines Shape the Next Healthcare Growth Phase

Aditi Sarkar

10 November 2026 03:00 PM AEDT

Drug Portfolios and Clinical Pipelines Shape the Next Healthcare Growth Phase

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Eli Lilly recently generated USD 24.4 billion Revenue as Demand supported its major medicine portfolios.
Johnson and recently Johnson reported USD 25.4 billion quarterly sales and raised its annual outlook.
AbbVie reported recently recently USD 17.4 billion quarterly revenue with growth across its immunology portfolio.
Each company disclosed distinct priorities covering current operations, financial performance and planned Business developments ahead.

Recent activity in therapies, medicine portfolios and medical technology is bringing attention to Eli Lilly and Company (NYSE:LLY), Johnson & Johnson (NYSE:JNJ) and AbbVie Inc. (NYSE:ABBV). Their announcements describe different revenue drivers, business priorities and reporting periods, while their November 9, 2026 share movements provide a snapshot of investor trading activity.

Eli Reports Its Latest Operating Results

Eli Lilly and Company reported results for the third quarter of 2026. Revenue grew 39% to USD 24.4 billion, supported primarily by Mounjaro and Zepbound. GAAP diluted EPS reached USD 7.22. Its exposure to metabolic medicines and pharmaceutical pipeline gives the company a distinct place in the broader healthcare theme. The figures reflect that company's own reporting period and operating mix. Eli shares closed at USD 1411.95 on November 9, 2026, up 4.28%, with Market Capitalisation of USD 1.33 trillion.

A Different Business Model Shapes the Next Comparison

Johnson & Johnson reported results for the third quarter of 2026. Sales rose 5.9% to USD 25.4 billion. Adjusted diluted EPS was USD 2.59; reported EPS reflected a special litigation-related charge. Its exposure to innovative medicines and medical technology gives the company a distinct place in the broader healthcare theme. The figures reflect that company's own reporting period and operating mix. Johnson shares closed at USD 282.11 on November 9, 2026, up 2.13%, with market capitalisation of USD 679.13 billion.

The Third Business Adds Another Dimension

AbbVie Inc. reported results for the third quarter of 2026. Net revenue rose 10.3% to USD 17.404 billion. Immunology revenue reached USD 9.165 billion, including Skyrizi revenue of USD 5.776 billion. Its exposure to immunology, neuroscience and oncology portfolios gives the company a distinct place in the broader healthcare theme. The figures reflect that company's own reporting period and operating mix. AbbVie shares closed at USD 293.30 on November 9, 2026, up 0.68%, with market capitalisation of USD 518.44 billion.

What Lies Ahead for the Group?

The companies have set out separate next steps rather than a shared forecast. Eli projects full-year 2026 revenue of USD 91 billion to USD 92 billion. Johnson increased its 2026 reported sales guidance midpoint to approximately USD 101.2 billion. AbbVie raised full-year adjusted diluted EPS guidance to USD 13.95–13.99. Taken together, their statements keep attention on product launches, clinical evidence and existing financial guidance; the timing and conditions attached to each plan remain company-specific. Their reported share-price changes describe the November 9 session only and do not establish future Investment outcomes.

FAQs

Q: What are the main developments covered?

A: Recent quarterly business results and operational priorities at Eli, Johnson and AbbVie.

Q: Do these results cover the same reporting period?

A: No. Each figure is assigned to the company’s stated fiscal reporting period.

Q: What comes next for the businesses?

A: Each company has described separate plans involving product launches, clinical evidence and existing financial guidance, subject to its own statements and conditions.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.